| 15.62 Data as of May 22 |  0.00 / 0.00%Today’s Change | 12.52 Today|||52-Week Range 21.99 | +4.48% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $99.1M |
Company Description
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. The company's product XIAFLEX is, an injectable collagenase enzyme, which is used for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm. Its two additional clinical indications include Peyronie's disease and frozen shoulder. BioSpecifics Technologies is also developing XIAFLEX internally for human and canine lipomas. The company was founded in 1990 and is headquartered in Lynbrook, NY.
Employees
Shareholders
| Individual stakeholders | 44.23% |
| Mutual fund holders | 28.73% |
| Other institutional | 11.09% |
Top Executives
| Thomas L. Wegman | Chairman, President, CEO, CFO, CAO & Secretary |
| James Goris | Controller |
.
